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Abstract
Background: The HIV epidemic in Peru is still regarded as concentrated - sentinel surveillance
data shows greatest rates of infection in men who have sex with men, while much lower rates are
found in female sex workers and still lower in the general population. Without an appropriate set
of preventive interventions, continuing infections could present a challenge to the sustainability of
the present programme of universal access to treatment. Determining how specific prevention and
care strategies would impact on the health of Peruvians should be key in reshaping the national
response.
Methods: HIV/AIDS prevalence levels for risk groups with sufficient sentinel survey data were
estimated. Unit costs were calculated for a series of interventions against HIV/AIDS which were
subsequently inputted into a model to assess their ability to reduce infection transmission rates.
Interventions included: mass media, voluntary counselling and testing; peer counselling for female
sex workers; peer counselling for men who have sex with men; peer education of youth in-school;
condom provision; STI treatment; prevention of mother to child transmission; and highly active
antiretroviral therapy. Impact was assessed by the ability to reduce rates of transmission and
quantified in terms of cost per DALY averted.
Results: Results of the analysis show that in Peru, the highest levels of HIV prevalence are found
in men who have sex with men. Cost effectiveness varied greatly between interventions ranging
from peer education of female commercial sex workers at $US 55 up to $US 5,928 (per DALY
averted) for prevention of mother to child transmission.
Conclusion: The results of this work add evidence-based clarity as to which interventions warrant
greatest consideration when planning an intervention response to HIV in Peru. Cost effectiveness
analysis provides a necessary element of transparency when facing choices about priority setting,
particularly when the country plans to amplify its response through new interventions partly funded
by the GFATM.
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Background
Patterns of the human immunodeficiency virus (HIV)
vary across countries and regions, and the most vulnera-
ble populations are not necessarily equivalent interna-
tionally or across continents. Recent data from the
Peruvian Ministry of Health states that as of 31 December
2007, 30,389 cases of HIV and 20,610 cases of acquired
immunodeficiency syndrome (AIDS) had been reported
in the general population since 1983[1,2]. The Peruvian
HIV epidemic is predominantly concentrated in men who
have sex with men (MSM), with lower rates found in
female sex workers (FSW) and lower still in the general
population[3,4], and virtually no cases are reported
amongst injecting drug users since such practice is rare in
Peru.
In 2001 the United Nations (UN) adopted a set of com-
mitments aimed at the prevention and treatment of HIV/
AIDS. Prior to implementation, analysis was performed to
determine the necessary resources and likely cost implica-
tions that this would entail[5]. In 2002, Stover et al[6]
attempted to determine the effect of expanding such pre-
ventative interventions on global transmission rates. Their
findings suggested that a further 29 million new infec-
tions could be prevented worldwide by 2010[5].
Here we attempt to evaluate potential HIV prevention
strategies in Peru in terms of their ability to reduce Disa-
bility Adjusted Life Years (DALYS) individually and in
combination. Whilst the epidemic in this country seemed
to have stabilized at least a decade ago, and antiretroviral
treatment (ART) has been offered free of charge by the
Ministry of Health since 2004, insufficient prevention
efforts might increase the cost of treatment and affect its
sustainability [1,7]. Moreover, a number of new preven-
tion projects are currently being funded by the Global
Fund for AIDS, Tuberculosis and Malaria (GFATM) in
Peru and other countries with similar epidemics. New
cost-effectiveness data from these projects can therefore
be used together with monitoring and evaluation to, if
necessary, revise planned interventions to ensure that new
resources are used in the most effective manner.
Methods
Baseline prevalence levels of HIV/AIDS in Peru
HIV prevalence levels in Peru were estimated using the
Estimation and Projection Package (EPP), following the
methodology as used by the Joint United Nations Pro-
gramme on HIV/AIDS and the World Health Organisa-
tion (WHO) in projecting the WHO/UNAIDS country
estimates [8-10]. Sentinel surveillance data, as used in
their country estimates [11,12], was incorporated in our
calculations of prevalence. The three main groups with
sufficient available sentinel data were: MSM, FSW and
pregnant women - the size of these groups and length of
time they are assumed to remain in these groups are pre-
sented in Table 1. Sentinel data was available for the
period 1985 to 2002 and for the MSM, FSW and pregnant
women groups there were a total of 21, 14 and 67 pub-
lished sentinel survey values used in the analysis[11,12].
National data was then estimated by applying the concen-
trated epidemic curves for the individual risk groups
countrywide. Baseline projections were calculated on the
assumption that behavioural changes do not occur in the
future. Full details of the methodology followed for this
work have been published elsewhere[10,13,14].
The GOALS model
The GOALS model has been used in previous global and
regional HIV analyses to assess the ability of a variety of
interventions against HIV/AIDS to reduce rates of trans-
mission in these regions [6,13]. The GOALS model is a
deterministic model that uses data in three main areas to
project HIV prevalence and incidence: demography; sex-
ual behaviour; and HIV and sexually transmitted infection
(STI) rates. GOALS considers four different risk groups,
the exact definition of which is specified by the user. For
the purposes of this analysis the groups were defined as:
MSM, FSW and their clients, men and women with multi-
ple sexual partners, and men and women in steady sexual
relationships.
Initial parameter ranges for behavioural and biological
inputs were specified based on a review of the available
literature (see Tables 2 and 3 for full details). Ten thou-
Table 1: Population risk groups and their associated estimated population size used in EPP analysis
Population Population size (15 years +) Details of estimation
MSM 620,978* Based on 2005 estimate [23]
FSW 25,500† 2002 figure (average) based national aids programme report to UNAIDS[49]
Pregnant women 587,000‡ 2005 Figures based on births per year[50]
Remaining population 26,040,522 2005 Figures from UN Population data base and calculated by subtracting populations 
from [50]
*MSM remain in this group for lifetime
† FSWs are estimated to remain in this population for an average of 5 years and return to remaining population afterwards
‡ Pregnant women remain in population for one year and return to remaining population afterwardsBMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
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sand simulations of the GOALS model were then com-
puted using @RISK software[15] to perform iterations
using the Monte Carlo simulation method. Each iteration
of the model sampled parameter values randomly from
the uniform distributions defined by the ranges detailed
in Tables 2 and 3. For each iteration, projected HIV prev-
alence levels for the period 1999 to 2004 were compared
to those calculated by the baseline EPP analysis described
in the last section which predicted baseline prevalence lev-
els for HIV in Peru based on sentinel survey data. The set
of behavioural and biological inputs within the GOALS
model that minimized the deviation of HIV prevalence
from the projected EPP analysis across the period 1999 to
2004 was then identified as the best-fit set of values to be
used within the subsequent calculations and analysis of
intervention effects.
Calculating the costs of interventions
Unit costs for prevention interventions (per person
reached) were calculated using a methodology published
jointly by Asian Development Bank, UNAIDS, Futures
Group International and Ease International[16]. The out-
puts of this software were specifically designed to work
with the GOALS model and have been implemented pre-
viously in Indonesia[16]. Unit costs applied in estimating
final values based upon on either: published Peruvian
data; field experience of local experts working at local
NGOs the authors held discussions with; or finally from
direct programme experience of the Peruvian-based
authors. Assumptions about personnel-to-participant
ratios presented in the supplementary material are based
upon values used in prior analysis[16] and expert local
opinion [see Additional file 1]. Detailed unit costs used to
Table 2: Behavioural parameters used in the GOALS model: Ranges and best fit values.
Input Min Max Best fit Source
Percent of men 15-49 that are sexually active 88.0 95.3 94.0 [39,51]
Percent of women 15-49 that are sexually active 74.8 95.5 91.0 [39,51]
Sexually active 15-19 as % of 15-49 54.2 76.8 67.0 [51]
MSM
Input Min Max Best fit Source
Percent of men in risk group 0.0 15.0 3.2 [23,39,46]
coital frequency (acts per year) 30 70 35.7 [13]
number of partners per year 1 6 1.2 [39]
Condom usage (percentage of acts) 24.3 55.6 53.6 [46]
High risk men
Input Min Max Best fit Source
Percent of men in risk group 4.0 36.0 4.4 [39,51]
coital frequency (acts per year) 2 70 10.0 [13,47]
number of partners per year 2 89 2.5 [13]
Condom usage (percentage of acts) 59.6 95.8 93.9 [7]
Medium risk men
Input Min Max Best fit Source
Percent of men in risk group category 5.0 16.0 12.4 [13,52]
coital frequency (acts per year) 30 70 31.0 [13]
number of partners per year 2 5 2.2 †
Condom usage (percentage of acts) 7.5 36.6 19.2 [51]
Low risk men
Input Min Max Best fit Source
Percent of men in risk group category * * * *
coital frequency (acts per year) 30 70 38.9 [13]
number of partners per year 1 2 1.1 †
Condom usage (percentage of acts) 0.0 28.9 23.8 [51]
Partners per year Women (percentage of total female population aged 15-49 in risk group)
Input Min Max Best fit Source
High risk (< 0.0%) 500 1200 559.5 [13,52]
Medium Risk (18.5%) 13 1 . 5 †
Low risk (81.5%) 12 1 . 0 †
*Determined as remainder of MSM, High and Medium risk groups
† Number of partners per year for the low and medium risk groups provides the basis of stratification by which the risk group is defined.BMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
Page 4 of 12
(page number not for citation purposes)
calculate the cost per person reached for each intervention
are presented in the supplementary material accompany-
ing this article [see Additional file 1].
Modelling HIV Interventions effects in Peru
Interventions individually against HIV, and then in com-
bination, were assessed against a "no intervention" sce-
nario, with the outcome measures of cost per infection
averted and DALYS [17] used to assess effectiveness. The
"no intervention" scenario was calculated by setting the
coverage of all other interventions other than those being
assessed, including condom usage, to zero. A number of
interventions are available in GOALS, those chosen for
inclusion in this study were:
￿ Mass media - media campaigns targeted at the gen-
eral population. Costing is based on an average cam-
paign price with four promotions per year - newspaper
inserts delivered to 7% of the population, 52 TV emis-
sions and 180 radio transmissions - reaching half of
the adult population.
￿ Voluntary counselling and testing - the number of
tests required is equal to twice the number of people
infected with HIV. It was assumed that people will
request a new test every five years.
￿ Peer counselling and treatment of sexually transmit-
ted infections for female sex workers- the need is
assumed to include all sex workers. Peer educators are
Table 3: Biological parameters used in the GOALS model: Ranges and best fit values.
MSM
Input Min Max Best fit Source
HIV prevalence 0.0 21.97 7.5 [12,24,46]
Prevalence of ulcerative STIs* 0.0 72.3 23.7 [23]
Prevalence of non-ulcerative STIs† 0.0 6.3 5.2 [53]
Percent of STI cases treated 84.1 87.1 85.3 [51]
High risk men
Input Min Max Best fit Source
HIV prevalence 0.7 13.8 7.3 [54]
Prevalence of ulcerative STIs* 0.02 29.9 10.4 [23,54]
Prevalence of non-ulcerative STIs† 0.7 6.2 5.8 [23]
Percent of STI cases treated 84.1 87.1 85.8 [51]
Medium risk men
Input Min Max Best fit Source
HIV prevalence 0.1 0.7 0.6 [54]
Prevalence of ulcerative STIs* 1.0 15.2 6.8 [54]
Prevalence of non-ulcerative STIs† 0.0 3.0 2.6 Assumption
Percent of STI cases treated 84.1 87.1 84.3 [51]
Condom usage
Low risk men
Input Min Max Best fit Source
HIV prevalence 0.1 0.6 0.6 [23,54]
Prevalence of ulcerative STIs* 0.8 7 3.3 [53]
Prevalence of non-ulcerative STIs† 0.0 4.7 2.8 [39,53]
Percent of STI cases treated 84.1 87.1 86.0 [51]
Women
Input Min Max Best fit Source
HIV prevalence - FSW 0.6 1.9 1.8 [12]
HIV prevalence - Medium 0.1 1.9 0.5 Assumption
HIV prevalence - Low 0.1 1.1 0.1 [12]
* For the purposes of this analysis, ulcerative STIs include: syphilis, chancroid and herpes simplex virus-2.
† For the purposes of this analysis, non-ulcerative STIs include: gonorrhea and chlamydia.BMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
Page 5 of 12
(page number not for citation purposes)
trained by health professionals and provide condoms
during counselling sessions.
￿ Peer counselling and treatment of sexually transmit-
ted infections for MSM - outreach programmes similar
to peer counselling for sex workers - condoms are pro-
vided during counselling sessions.
￿ Youth - includes children in the formal education
system aged between 10 and 18. Sessions occur during
normal school activities and are run by teachers who
have undergone specific training.
￿ Condoms - public sector condom distribution, male
type only. Demand is calculated by sexually active
population, proportion of sexually active population
in high and medium risk groups, number of partners,
and number of contacts per partner in each risk group.
Condoms are included as part of other interventions
including all peer education interventions and STI
treatment.
￿ STI treatment - Available to anyone requesting this
activity. Prevalence rates are specified for each risk
group in Table 3. Activity includes costs of treatment,
counselling and condom provision. Drugs costs based
on an average for treatment of urethral and vaginal
discharge, genital ulcers and pelvic inflammatory dis-
ease.
￿ Prevention of mother to child transmission -
includes counselling pre and post test, and nevirapine
for mother and child if accepted.
￿ Highly active antiretroviral therapy - based on the
three alternative treatment regimes proposed in a
report addressing the implementation of an antiretro-
viral programme for Peru [1]. The basic programme
includes: ARVS, Monitoring (CD4 + Viral Load). Inter-
mediate programme is comprised of: Basic pro-
gramme activities and imaging tests, additional lab
monitoring, administrative costs. The comprehensive
programme consists of: Intermediate programme
activities and treatment of opportunistic infections.
The interventions outlined above influence rates of HIV
transmission in GOALS by altering behavioural factors
including: rates of condom use; treatment of STIs; number
of sexual partners and age at first sex. This impact data was
determined by review of the literature initially reported in
2004[18] which has been periodically updated in the
GOALS model since and the version used in this analysis
was last updated in February 2006[19]. Full details of the
assumed impact of each intervention on rates of condom
use; treatment of STIs; number of sexual partners and age
at first sex is supplied in the supplementary material for
this article [see Additional file 1].
DALYS averted were calculated using the number of infec-
tions averted per year and translating this into a new fig-
ure of years of life lost (YLLs) due to premature death and
equivalent 'healthy' years lost due to disability (YLDs).
The full calculation of the DALYs uses the methodology
described by Fox-Rushby et al[20]. Spectrum was used to
project HIV incidence and deaths in 5 year intervals (ages
15-80+). Survivorship with HAART was calculated using
recently published Peruvian data[21].
Uncertainty Analysis
Many of the behavioural and prevalence values used in
the GOALS model have a level of uncertainty associated
with them and in order to analyse the effects these have on
the results, two sets of uncertainty analysis were carried
out. Firstly, the effectiveness of interventions was recalcu-
lated using the values of low, average and high interven-
tion effectiveness as included within the GOALS model
[see Additional file 1]. Additionally, 10 separate computa-
tions of the model were run using randomly chosen val-
ues for the behavioural and biological parameters that
created HIV prevalence rates which did not deviate by
greater than 50% from the baseline predictions. Only bio-
logical parameters listed in table 3 were included within
this analysis, those in the supplementary materials [see
Additional file 1 - Stable 9] accompanying this report were
not. Finally, a separate calculation of baseline prevalence
rates was carried out using a prior version of EPP[22] for
comparison of results.
Ethics
The study protocol was reviewed and approved by Univer-
sidad Peruana Cayetano Heredia's Independent Review
Board.
Results
Estimated prevalence levels of HIV in Peru - baseline 
projection data
The three main groups for which there were sufficient data
available to make estimates of prevalence were: female sex
workers, MSM and pregnant women. For 2008, the total
number of people living with HIV was estimated as
63,795, a prevalence of 0.32%. Prevalence levels for MSM,
FSW and pregnant women were 8.93%, 2.1%, and 0.15%
respectively.
Costs per person reached for prevention and treatment of 
HIV/AIDs
Table 4 summarises the unit costs per person reached by
the interventions for prevention and treatment activities.
Estimates for prevention activities were based on target
group sizes of 1000 people and therefore economies ofBMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
Page 6 of 12
(page number not for citation purposes)
scale were ignored. Personnel and peer educator costs
formed the highest proportion of most prevention strate-
gies and final values are therefore extremely sensitive to
assumptions about these values. Unit costs varied from
$US 8 per youth reached by peer educator, up to $US 124
per commercial sex worker reached. HAART costs varied
from $US 3379 for a basic programme to $US 3792 for a
comprehensive package.
Projections of the effects of interventions
Tables 2 and 3 detail what was calculated as the best fit set
of biological and behavioural parameters for the baseline
prevalence estimates in GOALS. Table 5 shows the results
for the number of infections averted and the cost effective-
ness of these interventions expressed in terms of cost per
infection averted and cost per DALY averted. The results
suggest that if cost effectiveness were the only considera-
tion when choosing which interventions to implement
first then peer education of female sex workers, blood
safety, peer education of youth in school and voluntary
counselling and testing would be ranked ahead of others.
Blood safety, condom distribution, and peer education of
both, youth in school and MSM, provided the greatest
rates of total infections averted. However, it must be noted
that these values of total infections averted should not be
compared against current epidemiological estimates as
they do not take into account existing interventional
impacts on condom usage, treatment of STIs and reduc-
tion in high risk behaviour which were set to zero for the
purposes of this part of the analysis.
Figure 1 shows the incremental benefits of each additional
intervention as it is added to the package of interventions.
The order in which interventions were added is based
entirely upon the average cost effectiveness ratio ($/DALY
averted) as detailed in Table 5.
Sensitivity of the analysis to changes in intervention 
impacts
A series of sensitivity analyses were carried out to deter-
mine the impact of various assumptions within the model
on the relative rankings of the cost effectiveness of each
intervention. The effectiveness of interventions was recal-
culated using the values of low, average and high interven-
tion effectiveness as included with the GOALS model. The
effectiveness of interventions had impacts on the follow-
ing factors: rates of condom use; treatment of STIs;
number of sexual partners and age at first sex. Increasing
the interventional effectiveness to a higher level had very
little impact on the rankings apart from voluntary coun-
selling and testing moved ahead of blood safety. Reducing
the rankings to a lower level had more of an impact on the
ranking of interventions: blood safety became the most
cost effective, followed by peer education of youth and
then voluntary counselling and testing.
In addition to this, 10 separate computations of the
model were run using randomly chosen values for the
behavioural and biological parameters that created HIV
prevalence rates which did not deviate by greater than
50% from the baseline predictions. This analysis showed
that for total infections averted over the five year period
youth in-school, condoms and FSW showed the greatest
absolute range of values, and blood safety, mass media
and MSM interventions varied the least. In terms of rank-
ings of the interventions based upon average cost effec-
tiveness ratio ($/DALY averted) the model remained fairly
stable. FSW and MSM both varied by only one place, the
most variation across the rankings was shown by youth
education (varying from first to fifth place) and condoms
(varying from fourth to seventh place).
A separate calculation of baseline prevalence rates was car-
ried out using a prior version of EPP[22] for comparison.
Main differences in the modelling of data between the two
versions were that the newer version of the software
Table 4: Unit costs per person reached by intervention in 2008 
$US.
STI treatment $US
Cost per STI case treated 3.7
Youth $US
Cost per youth reached by peer educator 8.0
Cost per teacher trained 62.0
Commercial sex worker $US
Cost per sex worker reached 124.0
Mass media $US
Cost per person reached with mass media 0.4
MSM $US
Cost per person reached 103.0
Voluntary counselling and testing $US
Total costs per client 40.0
Prevention of mother to child transmission $US
Cost per mother and child treated 23.2
Antiretroviral programmes* $US
Basic† 3379
Intermediate‡ 3788
Comprehensive§ 3792
Further details of the individual unit costs and assumptions made for 
each intervention are provided in the supplementary materials that 
accompany the manuscript [see Additional file 1].
*Costing for highly active antiretroviral therapy (HAART) were 
computed based on local protocols and prior analysis[1].
† Antiretrovirals, Monitoring (CD4 + Viral Load)
‡ Basic programme + Imaging tests, additional lab monitoring, 
administrative costs
§ Intermediate programme + treatment of opportunistic infectionsBMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
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allows more accurate initial estimates of prevalence for
individual risk groups and allows reassignment of popu-
lations between risks groups which particularly impacts
the FSWs modelling in this work. Results of this analysis
showed that for 2008, the total number of people living
with HIV was estimated as 62,910; 43,799 of which were
male, and 19,112 female. Prevalence levels for MSM,
commercial sex workers and pregnant women were 9.0%,
0.8%, and 0.2%, respectively. The expansion pathway
resulting from this analysis showed, blood safety, peer
education of sex workers, peer education of youth in
school and voluntary counselling and testing to be the
most cost effective order.
Discussion
The primary aim of this analysis was to determine how an
intervention response to HIV could be most cost effec-
tively implemented in Peru. This analysis provides esti-
mates of historical and future levels of HIV based on the
best available data and using methods currently recom-
mended by UNAIDS in producing country estimates.
Using these baseline prevalence estimates, an evaluation
Table 5: Interventions against HIV/AIDS and their associated coverage levels, total costs, yearly costs, yearly infections averted, yearly 
DALYS averted and sorted by average cost effectiveness
Intervention Coverage 
level (%)
Total costs ($ 
Millions) 
2008-2013
Yearly costs 
($ Millions)
Total 
infections 
averted 
(2008-2013)
Yearly 
infections 
averted
Yearly 
DALYS 
averted
Average cost 
effectiveness - 
$/DALY 
averted 
(range*)
FSW 50 0.6 0.1 1,970 394 10,118 55 (2 - 124)
FSW 95 1.0 0.2 3,730 746 19,157 55 (1 - 105)
FSW 80 0.9 0.1 3,130 626 16,076 55 (2 - 116)
Blood safety 50 5.3 0.9 13,050 2,610 67,025 79 (41 - 79)
Blood safety 80 8.5 1.4 20,570 4,114 105,648 80 (43 - 80)
Blood safety 95 10.1 1.7 24,260 4,852 124,599 81 (43 - 91)
VCT 95 8.2 1.4 13,870 2,774 71,236 116 (18 - 116)
VCT 50 4.4 0.7 7,300 1,460 37,493 118 (18 - 118)
VCT 80 7.1 1.2 11,670 2,334 59,937 118 (18 - 118)
Youth: in-
school
50 13.7 2.3 21,760 4,352 131,126 104 (12 - 177)
Youth: in-
school
80 22.0 3.7 22,760 4,552 137,152 161 (19 - 270)
Youth: in-
school
95 26.2 4.4 23,020 4,604 138,719 189 (12 - 630)
mass media 50 11.3 1.9 8,930 1,786 45,864 246 (89 - 253)
Condoms 95 61.0 10.2 23,740 4,748 121,929 500 (64 - 500)
Condoms 80 51.3 8.6 19,890 3,978 102,155 503 (62 - 503)
Condoms 50 32.1 5.3 12,430 2,486 63,840 503 (58 - 503)
STI treatment 50 25.1 4.2 6,600 1,320 33,898 739 
(200 - 1021)
STI treatment 80 40.1 6.7 10,290 2,058 52,849 759 
(199 - 1045)
STI treatment 95 47.6 7.9 12,080 2,416 62,043 767 
(200 - 1055)
MSM 50 75.0 12.5 11,090 2,218 56,958 1,317 
(354 - 1317)
MSM 80 120.0 20.0 17,570 3,514 90,240 1,330 
(351 - 1330)
MSM 95 142.5 23.8 20,770 4,154 106,675 1,336 
(350 - 1336)
HAART
Comprehens
ive
95 37.7 6.3 - - 18917 1995
Intermediate 95 37.7 6.3 - - 16412 2297
Basic 95 33.6 5.6 - - 13999 2403
PMTCT 80 246.4 41.1 10,460 2092 41,557 5,928 
(2313 - 5.928)
*Ranges based upon sensitivity analysis whereby the model was run using randomly generated values for the behavioural and biological parameters 
which were varied so that HIV prevalence rates did not deviate by greater than 50% from the baseline predictions.BMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
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of the cost effectiveness of a series of separate interven-
tions aimed at reducing the levels of HIV transmission for
the period 2008 - 2013 has been carried out.
Estimates for the number of people living with HIV in
Peru vary widely depending on the source, and range from
20,000 to 144,000 [23]. Levels predicted by this work for
2007 were 62,450 which are between these limits and in
the lower range of those predicted by UNAIDS (57,000 to
97,000 people living with HIV/AIDS for 2007)[24] for the
same year.
In 1993 the first global comparison of a large number of
interventions against a range of diseases determined that
interventions costing less than US$1000 per DALY averted
were cost-effective[25]. However, a more up to date set of
criteria suggested by the Commission on Macroeconom-
ics and Health states that interventions costing less than
three times GDP per capita to avert each DALY are cost-
effective[26]. Using the second of these two definitions of
cost effectiveness, and considering Peru's GDP per capita
was US$7,600 in year 2007[27], all of the interventions
included in this study would be regarded as cost-effective.
The inclusion of HAART within this analysis may be con-
sidered controversial. After years of campaigning for
access to treatment we are not intending to undermine
HIV positive Peruvians their fundamental right to treat-
ment. However, the finding that HAART is one of the
more costly interventions will come as no surprise and is
consistent with other studies using similar methodolo-
gies[13]. Whilst HAART is one of the most expensive
options, it remains cost effective by the definitions out-
lined above and without any doubt should be included in
any package against HIV in Peru. Importantly, our esti-
mates of average cost effectiveness ratios (between $US
1995 for a basic programme to $US 2403 for a compre-
hensive package $/DALY averted) are in a similar range to
Expansion pathway for incremental addition of interventions - based upon the average cost effectiveness ratio ($/DALY  averted) Figure 1
Expansion pathway for incremental addition of interventions - based upon the average cost effectiveness ratio 
($/DALY averted). 1= FSW 95% coverage; 2 = 1 + Blood safety 95% coverage; 3 = 2 + Youth: in-school 50% coverage; 4 = 
3 + VCT 95% coverage; 5 = 4 + Youth: in-school 95% coverage; 6 = 5 + mass media; 7 = 6 + Condoms 95% coverage; 8 = 7 + 
STI treatment 95% coverage; 9 = 8 + MSM 95% coverage; 10 = 9 + HAART comprehensive; 11 = 10 + PMTCT 80% coverage.
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those presented in another study that estimated cost effec-
tiveness for antiretroviral therapy for Africa in 2002 as
between $US1100 and $US1800[28]. Another study look-
ing at the regions of sub-Saharan Africa and South East
Asia found that antiretroviral therapy in these areas was
calculated to cost between $Int 542 and $Int 2010 - $Int
being a hypothetical currency that have the same purchas-
ing power that the $US has in the United States at any
given point[13].
As with any exercise in cost-effectiveness estimation, this
analysis is not free from limitations which warrant cau-
tion when considering the implications of the results pre-
sented. Deciding what interventions to include was
determined by three factors: whether the intervention was
included in the GOALS model; whether sufficient infor-
mation was available for its inclusion in the model[19];
and whether an intervention was deemed locally appro-
priate. The set of interventions chosen as a result of this
work may not therefore represent the best case scenario
and more appropriate options may exist. It is important to
note that of all the studies used in determining the impact
of interventions within the GOALS model, only very few
of these were actually carried out in Latin America[18,29-
37]. Although reproducibility in Latin America should be
possible, their impact may vary in comparison to the ini-
tially reported studies, which would have an effect on
their cost effectiveness when applied in Peru.
The higher risk groups which the interventions in this
model are targeted at are presented in this paper as dis-
crete cohorts. However, as many papers in Peru have sug-
gested, this categorisation of people based on certain
behaviours or sexual preferences not only excludes certain
groups at higher risk, but includes others inappropriately
[38-41]. The GOALS model, as it currently stands, does
not allow for full mixing between the at risk groups over
the analysis period which would differ from reality, as for
example, some high risk will move to the low risk group
over the time course of the analysis. This lack of sub-cate-
gorisation, mixing over time of the groups within the
analysis over time, and the associated limitations is
acknowledged, however, carrying out the analysis in this
way allows a certain amount of comparability across stud-
ies by replicating methods and techniques applied else-
where [5,6,10,13,19,42].
It is suggested that due to levels of uncertainty in the
assumptions used in the model, interpretation of results
should be based on broad categories of cost effectiveness
rather than the absolute levels of infections preventable
per intervention. The rankings suggested by this analysis
are meant as a guide only and the exact order should not
be taken as an absolute, as demonstrated by the sensitivity
analysis. The values presented in table 5 should not be
compared to current epidemiological estimates as they do
not take into account existing interventional impacts on
condom usage, treatment of STIs and reduction in high
risk behaviour, which were set to zero. As a result, data
must be interpreted with caution by policy makers as it
does not include interventions which are currently occur-
ring. The necessary information required to make such an
assessment of interventions compared to current efforts
levels is unfortunately lacking in many areas at present.
Apart from the uncertainties within the analysis, there are
other legal and social factors to consider when weighing
up the results of this cost effectiveness analysis such as the
increasing perception of certain services as rights and
social legitimacy. Such factors are even more pertinent for
the MSM and FSW interventions where the stigma associ-
ated with membership of these groups leads to the avoid-
ance of people assuming the identity of these at risk
groups. Although the uncertainty analysis in the study
goes some way to addressing infectivity and the clinical
stage of HIV/AIDS, practical issues such as these which
impact on clinical management of patients, were ignored
by this analysis.
The ability of HAART to impact on sexual behaviour and
transmissibility was not included in this analysis as this
facility is not currently included in the interventional
impacts in the GOALS model. Consequently this analysis
may underestimate the actual cost effectiveness of this
intervention. Precise and reliable estimates regarding the
behavioural and biological inputs required for the model
were limited and many figures used in the analysis were
based on studies of small numbers of subjects. In some
areas in particular, such as number of coital acts per year
and number of partners per year for some of the risk
groups, no data existed resulting in assumptions being
made regarding this data. As called for in another article
[4] this data should be collected as a matter of priority in
order that more accurate analysis is carried out in the near
future.
Unit costs calculated by the analysis were substantially
influenced by personnel and peer educator costs. Final
results are therefore sensitive to assumptions about these
values. Values for the unit costs per person reached varied
from $US 8 per youth reached up to $US 3792 for a com-
prehensive HAART programme. These HAART values
appeared reasonable when compared with other such cal-
culations (estimated values between $US395 and $US
5400 for various countries in Latin America)[5,43,44] and
on the whole represented good value for money.
The expansion pathway, calculated by adding interven-
tions to each other in order of their cost effectiveness,
gives an idea of the levels of synergy that occur by havingBMC Public Health 2009, 9:352 http://www.biomedcentral.com/1471-2458/9/352
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multiple intervention strategies and the costs associated
with such packages of interventions. As with another
study[13], the expansion pathway follows an exponential
trajectory as the more expensive interventions are added
to the overall strategy.
Peer education of sex workers, mass media, treatment of
STIs and voluntary counselling and testing were found to
be the four most cost effective interventions in a similar
analysis based on South East Asia[13] - blood safety was
not included in this analysis. The results of this study sug-
gest that peer education of sex workers, blood safety, peer
education of youth in school and voluntary counselling
and testing would all substantially reduce the burden of
HIV/AIDS in Peru and are economically attractive when
using the international accepted definitions based on cost
per DALY averted. Although the epidemic of HIV in Peru
presents a concentrated high-risk group pattern, with
MSM presenting the highest concentration of prevalence,
blood safety was shown to be a very cost effective measure
because of its broad population based effect. It is impor-
tant to note that since coverage of blood screening is
already nearly 100%, the conclusion we suggest is drawn
from this result is that the model supports that blood
screening should continue because it is so cost-effective,
not that more infections could be averted by better blood
screening.
STIs within the model are broadly split into non-ulcera-
tive and ulcerative. This simplification assumes that HSV2
(along with syphilis and chancroid with which it is classi-
fied) is curable and has a higher rate of transmission than
it does in reality, which is noted as a limitation of this par-
ticular model by the authors. We also note the current
growing consensus that treatment of STIs, especially in
generalized epidemics, appears to have a minimal popu-
lation level effect, and the growing evidence to support
male circumcision which is not currently included within
the GOALS model[45].
Interventions targeted at MSM consistently performed
well in terms of total infections averted, ranking in the top
three, however, it did not perform well in terms of cost
effectiveness. Much of this lack of performance can be
explained by the inability of the model to compute spe-
cific sub-populations of MSM - classifying them as a single
homogeneous at risk group ignores the reality of varying
behavioural and risk characteristics[39,40,46-48]. If inter-
ventions were targeted more specifically at these groups
then numbers of participants included would be smaller
and the interventions would likely to improve signifi-
cantly in the cost effectiveness rankings. Unusually for a
concentrated epidemic, youth education in school has a
large impact on the number of infections averted. This
appears to be mainly due to sensitivity of the model to
interventions on medium risk groups, which although
representing a smaller prevalence, represent a large
number of sexual acts performed.
Conclusion
This analysis has determined how an intervention
response to HIV could be most cost effectively imple-
mented in Peru. HIV prevalence levels over time for vari-
ous at risks groups were estimated; country-specific unit
costs for a set of prevention and treatment interventions
were calculated and a potential cost-effective expansion
pathway is presented. The results of this work add evi-
dence-based clarity as to which interventions warrant
greatest consideration when planning an intervention
response to HIV in Peru. Cost effectiveness analysis pro-
vides a necessary element of transparency when facing
choices about priority setting with limited resources, but
is equally important in an era of unprecedented resources
for HIV in Peru and many other countries, and should be
considered together with criteria regarding social inclu-
sion and the universal right to health. Likewise, new evi-
dence regarding effectiveness of specific interventions is
fundamental, as is the design of new structural interven-
tions to alter their social origin (such as those that create
vulnerability) rather than its effects.
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